Marie Bosslett, Assistant Editor

Discover innovative research pearls at the Elevate-Derm Summer Conference 2025, focusing on psoriasis, skin cancer, and more.

New findings at Elevate Derm highlight remibrutinib's rapid and sustained efficacy in reducing chronic spontaneous urticaria symptoms, offering hope for patients.

Join Dermatology Times at the 2025 Elevate-Derm Summer Conference for expert insights and live updates from Park City, Utah.

Updated research finds that chronic stress disrupts healing processes and scar treatments, limiting the effectiveness of wound care in some patients.

Sun Pharma reveals promising phase 3 results for tildrakizumab (Ilumya) in treating PsA, showing significant symptom improvement in patients.

According to new research from Steven Dayan, MD, FACS, PROs are reshaping aesthetic medicine, enhancing Botox treatment insights and prioritizing holistic patient care.

The 2025 Fall Clinical Dermatology Conference energized PAs and NPs with innovative strategies, addressing burnout, digital branding, and personalized medicine.

In case you missed it, this week we had news about the launch of deuruxolitinib for alopecia areata, Treg cel impairment in vitiligo, the top aesthetic innovations of this month, and more.

New research highlights the significant impact of dermatological diseases on work-life balance, revealing greater burdens for women compared to men.

Global acne burden in reproductive-age women has risen significantly, with greater increases expected by 2040.

New survey data reveals gaps in atopic dermatitis treatment for pregnant women, highlighting the need for updated guidelines and better physician education.

A first-of-its-kind study reveals artificial intelligence (AI)-driven insights on hair loss trends, highlighting the impact of genetics, hormones, and COVID-19 on alopecia.

Discover how trifarotene, a novel retinoid, effectively addresses adult acne and its long-term effects, enhancing skin health and quality of life.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of July.

Haut.AI has launched the SPF Truth Booth and SPF Protection Power List, using AI to promote sun safety and personalized patient insights.

At a recent Dermatology Times Case-Based Roundtable event, Gaurav Singh, MD, MPH, FAAD, FACMS, utilized 3 patient cases to explore the role of GEP testing in melanoma and SCC.

Miiskin is transforming dermatologic care through telehealth, enhancing access, efficiency, and patient relationships, according to Ryan Trowbridge, MD, MS, MA, FAAD.

In case you missed it, this week we had news about the FDA's RPD Designation of QRX003 for Netherton Syndrome, Galderma's 2 new clinical trials of nemolizumab, Allergan Aesthetics' sPMA for SKINVIVE by Juvéderm, and more.

Robin Smith, MD, MBA, discusses the future of regenerative aesthetics and her exosome-based skin care and hair care brand, Exoceuticals.

A new paper highlights Alphyn Biologics' Zabalafin Hydrogel as a promising multitarget therapy for atopic dermatitis, addressing inflammation, itch, and bacterial complications.

Robin Smith, MD, MBA, champions exosome-powered skincare for long-lasting skin health and personalized regenerative aesthetics solutions for patients.

Discover how Robin Smith, MD, MBA, revolutionizes skin care with Exoceuticals, harnessing exosomes for advanced regenerative aesthetics and skin health solutions.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of July.

Learn more about the in-depth topics covered in the June 2025 print issue of Dermatology Times.

Dermatology Times is looking back on the top stories in dermatology from the month of June.

Quoin Pharmaceuticals advances QRX003 for Netherton Syndrome, receiving FDA's RPD Designation and showing promising clinical results.

Nektar Therapeutics reveals positive results from the REZOLVE-AD study, showcasing rezpegaldesleukin's efficacy in treating moderate to severe AD.

Almirall showcased groundbreaking research on atopic dermatitis, psoriasis, and actinic keratosis at the 2025 ICD.

Galderma launches clinical trials for nemolizumab, targeting systemic sclerosis and chronic pruritus of unknown origin, addressing critical patient needs.

Abeona Therapeutics' VIITAL trial reveals promising results for RDEB treatment, showcasing significant wound healing and pain relief with Zevaskyn therapy.